Novartis’ Beovu (brolucizumab) Receives EC’s Approval for Wet Age-Related Macular Degeneration

 Novartis’ Beovu (brolucizumab) Receives EC’s Approval for Wet Age-Related Macular Degeneration

Novartis’ Beovu (brolucizumab) Receives EC’s Approval for Wet Age-Related Macular Degeneration

Shots:

  • The EC’s approval is based on P-III HAWK (6/3mg) & HARRIER (6mg) study assessing Beovu [q12w/q8w with the majority on q12w following the loading phase) vs aflibercept 2 mg in 1,800 patients with wet AMD across 400 centers
  • The two P-III studies resulted in meeting its 1EPs i.e. gain in BCVA @48wks., it demonstrated superior resolution of retinal fluid (IRF/SRF) (for 6mg (31% & 26% vs 45% & 44%), superfluid resolution @16wks. & 1yr., maintenance of 3mos. dosing interval @1yr. (56% & 51%) respectively
  • Beovu (RTH258) is the only anti-VEGF therapy approved in the EU for wet AMD offering the option to start eligible patients on 3mos. dosing intervals immediately after the loading phase. The approval is applicable to all 27 EU states including the UK, Iceland, Norway, and Liechtenstein

Click here ­to­ read full press release/ article | Ref: Novartis | Image: WSJ

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post